The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR...

Descripción completa

Detalles Bibliográficos
Autores: Van Weelden, Willem Jan, Reijnen, Casper, Küsters-Vandevelde, Heidi V. N, Bulten, Johan, Bult, Peter, Leung, Samuel, Visser, Nicole C.M., Santacana Espasa, Maria, Bronsert, Peter, Hirschfeld, Marc, Colás, Eva, Gil-Moreno, Antonio, Reques, Armando, Mancebo, Gemma, Huvila, Jutta, Koskas, Martin, Weinberger, Vit, Bednaříková, Markéta, Hausnerova, Jitka, Snijders, Marc P. L. M., Matias-Guiu, Xavier, Amant, Frederic
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/72826
Acceso en línea:https://doi.org/10.1016/j.humpath.2020.12.003
http://hdl.handle.net/10459.1/72826
Access Level:acceso abierto
Palabra clave:Endometrial cancer
Estrogen receptor
Progesterone receptor
Cutoff
Prognostic biomarker
id ES_7c91a67a89a01c3cdc9c3add3dee6a7e
oai_identifier_str oai:repositori.udl.cat:10459.1/72826
network_acronym_str ES
network_name_str España
repository_id_str
spelling The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration studyVan Weelden, Willem JanReijnen, CasperKüsters-Vandevelde, Heidi V. NBulten, JohanBult, PeterLeung, SamuelVisser, Nicole C.M.Santacana Espasa, MariaBronsert, PeterHirschfeld, MarcColás, EvaGil-Moreno, AntonioReques, ArmandoMancebo, GemmaHuvila, JuttaKoskas, MartinWeinberger, VitBednaříková, MarkétaHausnerova, JitkaSnijders, Marc P. L. M.Matias-Guiu, XavierAmant, FredericEndometrial cancerEstrogen receptorProgesterone receptorCutoffPrognostic biomarkerThere is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1–2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1–30%. Sensitivity was highest for the cutoff values of 80–90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0–10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9–83.3%); 20–80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0–93.9%); and 90–100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8–100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0–10%), intermediate-risk (20–80%), and low-risk (90–100%) group.Elsevier2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionhttps://doi.org/10.1016/j.humpath.2020.12.003http://hdl.handle.net/10459.1/72826reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésVersió acceptada del document publicat a https://doi.org/10.1016/j.humpath.2020.12.003Human Pathology, 2021, vol. 109, p. 80-91cc-by-nc-nd (c) Elsevier, 2021info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/oai:repositori.udl.cat:10459.1/728262026-06-24T12:42:17Z
dc.title.none.fl_str_mv The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
title The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
spellingShingle The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
Van Weelden, Willem Jan
Endometrial cancer
Estrogen receptor
Progesterone receptor
Cutoff
Prognostic biomarker
title_short The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
title_full The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
title_fullStr The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
title_full_unstemmed The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
title_sort The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
dc.creator.none.fl_str_mv Van Weelden, Willem Jan
Reijnen, Casper
Küsters-Vandevelde, Heidi V. N
Bulten, Johan
Bult, Peter
Leung, Samuel
Visser, Nicole C.M.
Santacana Espasa, Maria
Bronsert, Peter
Hirschfeld, Marc
Colás, Eva
Gil-Moreno, Antonio
Reques, Armando
Mancebo, Gemma
Huvila, Jutta
Koskas, Martin
Weinberger, Vit
Bednaříková, Markéta
Hausnerova, Jitka
Snijders, Marc P. L. M.
Matias-Guiu, Xavier
Amant, Frederic
author Van Weelden, Willem Jan
author_facet Van Weelden, Willem Jan
Reijnen, Casper
Küsters-Vandevelde, Heidi V. N
Bulten, Johan
Bult, Peter
Leung, Samuel
Visser, Nicole C.M.
Santacana Espasa, Maria
Bronsert, Peter
Hirschfeld, Marc
Colás, Eva
Gil-Moreno, Antonio
Reques, Armando
Mancebo, Gemma
Huvila, Jutta
Koskas, Martin
Weinberger, Vit
Bednaříková, Markéta
Hausnerova, Jitka
Snijders, Marc P. L. M.
Matias-Guiu, Xavier
Amant, Frederic
author_role author
author2 Reijnen, Casper
Küsters-Vandevelde, Heidi V. N
Bulten, Johan
Bult, Peter
Leung, Samuel
Visser, Nicole C.M.
Santacana Espasa, Maria
Bronsert, Peter
Hirschfeld, Marc
Colás, Eva
Gil-Moreno, Antonio
Reques, Armando
Mancebo, Gemma
Huvila, Jutta
Koskas, Martin
Weinberger, Vit
Bednaříková, Markéta
Hausnerova, Jitka
Snijders, Marc P. L. M.
Matias-Guiu, Xavier
Amant, Frederic
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Endometrial cancer
Estrogen receptor
Progesterone receptor
Cutoff
Prognostic biomarker
topic Endometrial cancer
Estrogen receptor
Progesterone receptor
Cutoff
Prognostic biomarker
description There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1–2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1–30%. Sensitivity was highest for the cutoff values of 80–90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0–10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9–83.3%); 20–80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0–93.9%); and 90–100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8–100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0–10%), intermediate-risk (20–80%), and low-risk (90–100%) group.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1016/j.humpath.2020.12.003
http://hdl.handle.net/10459.1/72826
url https://doi.org/10.1016/j.humpath.2020.12.003
http://hdl.handle.net/10459.1/72826
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió acceptada del document publicat a https://doi.org/10.1016/j.humpath.2020.12.003
Human Pathology, 2021, vol. 109, p. 80-91
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Elsevier, 2021
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv cc-by-nc-nd (c) Elsevier, 2021
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411600005332992
score 15.81155

Similares en LA Referencia